艾迪注射液协同DP方案改善女性晚期肺癌临床疗效  

Clinical Efficacy of Aidi Injection Combined with DP Chemotherapy Regimen for Female Advanced Lung Cancer

作　　者：柏茂树[1] 王熙才[2] 罗露[2] 刘继明[1] 熊良庚[1] 梁百武 

机构地区：[1]达州市中西医结合医院,四川达州635000 [2]昆明医科大学第三附属医院,云南省肿瘤研究所,昆明650118

出　　处：《中国实验方剂学杂志》2016年第9期133-138,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家自然科学基金项目(81460358)

摘　　要：目的:评价艾迪注射液协同多西他赛联合顺铂(DP)方案化疗对女性晚期非小细胞肺癌(NSCLC)患者的疗效、免疫功能和生活质量的影响。方法:回顾性分析79例晚期女性NSCLC患者,按照治疗情况分为治疗组41例和对照组38例。治疗组采用艾迪注射液联合DP方案化疗,对照组单用DP方案化疗。21 d为1个周期,2个周期后进行评价。结果:治疗组有效率51.2%,对照组39.5%;治疗组疾病控制率82.1%,对照组66.7%,治疗组优于对照组(P<0.05)。治疗组治疗后CD_3^+,CD_4^+,CD_4^+/CD_8^+较治疗前及对照组治疗后增加,CD_8^+降低(P<0.05,P<0.01)。治疗组治疗后生理状况、社会和家庭状况及总量表分值较治疗前及对照组治疗后提高(P<0.05,P<0.01)。毒副反应集中体现在骨髓抑制和胃肠道反应两方面;其中,治疗组Ⅲ/Ⅳ度白细胞减少及血红蛋白减少低于对照组(P<0.05,P<0.01)。结论:艾迪注射液联合DP方案可以提高女性MSCLC患者的疗效、细胞免疫功能状态、生活质量情况,且降低毒副反应,值得临床推广应用。Objective： To investigate the efficacy of Aidi injection combined with doctaxel combined with cisplatin（ DP） chemotherapy regimen in female patients with advanced non-small cell lung cancer（ NSCLC）,and observe its effect on cellular immune function and quality of life. Method： We retrospectively analyzed clinical data of seventy-nine patients with advanced NSCLC. According to treatment regimens,they were divided into treatment group（ 41 cases） and control group（ 38 cases）. Patients in control group were treated with DP regimen only,while patients in treatment group were treated with Aidi injection combined with DP chemotherapy regimen. Treatment for 21 days was regarded as one cycle,and evaluation was conducted after two cycles. Result：Efficacy was 51. 2% in treatment group and 39. 5% in control group. Disease control rate was 82. 1% in treatment group and 66. 7% in control group,with statistically significant difference between two groups（ P〈0. 05）. In treatment group,counts of CD3＋T cells,CD4＋T cells and CD4＋/ CD8＋after treatment were significantly higher than those before treatment and those in control group,while the count of CD8＋T cells was decreased（ P〈0. 05,P〈0. 01）. In treatment group,scores of domains in physiological status,social and family status and total scores after treatment were improved than those before treatment and those in control group（ P〈0. 05,P〈0. 01）. Major adverse effects included bone marrow suppression and gastrointestinal reactions. Incidences of leukopenia of Ⅲ / Ⅳdegree and decreased hemoglobin in treatment group were lower than those in control group, with statistically significant difference between two groups. Conclusion： Aidi injection combined with DP regimen could improve the efficacy,cellular immune function and quality of life in female patients with advanced NSCLC. Furthermore,it could decrease toxic and adverse effects,so it is worthy of further clinical application and promotion.

关 键 词：艾迪注射液 肺肿瘤 多西他赛联合顺铂方案 免疫功能 

分 类 号：R287[医药卫生—中药学]